The Filing Desk

biote

BTMD · Nasdaq · Health Care · Financials, fiscal 2021 to 2025

BTMD · Last close · November 19, 2026
$0.84
Value biote yourself

biote's revenue fell 2.5% to $192 million in fiscal 2025. Its operating margin was 18.5%, up from 16.0% a year earlier. Free cash flow was $30 million, down 22.2%. It paid out $5 million in dividends and buybacks, 17% of free cash flow. The diluted share count rose 7.0%.

biote Corp. Latest fiscal year ended December 31, 2025 10-K filed March 13, 2026 · 0001193125-26-106099 Updated
Revenue
$192M
2.5%
Operating margin
18.5%
2.5 pts
Net income
$27M
756.7%
Free cash flow
$30M
22.2%
Return on equity
—
 
Market cap
$23M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What biote does

biote trains doctors and other medical practitioners to run hormone therapy practices, mostly for women going through menopause and men with low testosterone. Its program, the Biote Method, includes training and certification, software that helps set each patient's dose and track inventory, marketing support for the clinic, and access to outside compounding pharmacies that make the hormone pellets the practitioners prescribe. The company compares the setup to a franchise. Patients pay the clinics directly, rather than through insurance.

It makes money in two ways: fees that partner clinics pay under long-term service agreements, charged per procedure, and sales of its own brand of dietary supplements, which practitioners recommend to their patients. It reports one business segment. Revenue was $192.2 million in 2025, against $197.2 million in 2024.

At the end of 2025 biote worked with over 9,200 certified practitioners in more than 5,300 partner clinics across the United States. Its business is concentrated in 10 core states, which brought in about 53% of its revenue. It also owns Asteria Health, one of the facilities that compound hormones for its practitioners.

Its biggest risks, as it describes them

  • The Biote Method and its supplements may not win enough acceptance among clinics, practitioners and patients.
  • Its reliance on a few compounding pharmacies and contract makers, whose failures could hurt patients and its reputation.
  • Regulators could tighten rules on compounded bioidentical hormones, which would sharply affect its revenue.
  • Its practitioners and clinics are concentrated in a few regions of the country.
  • Weaknesses in its financial reporting controls, which led it to restate earlier financial statements.
From biote's annual report on Form 10-K, filed March 13, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2023 to 2025, earnings per share grew 138.6% a year and net income 186.0% a year, as new shares raised the share count by 43% and diluted each share's earnings.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments079893924
Debt incl. finance leases37122116109103
Net debt (negative means net cash)3743277079
Net debt to EBITDA1.0x—0.8x2.0x2.0x
Debt to equity9.0x————
Interest coverage23.6x−13.7x3.0x3.3x4.5x
Current ratio2.7x5.4x5.5x1.3x1.2x
Quick ratio2.2x4.8x4.7x1.0x0.8x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project biote's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What biote says to expect

  • Full year 2026: dietary supplements revenueWe continue to expect full-year 2026 dietary supplements revenue to grow at a mid- to high-single-digit rate from 2025.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 4, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $202,204 of biote shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Aug 11, 2026Marc D BeerExecutive Chairman, DirectorBought16,000$1.55$24,800Form 4
Aug 10, 2026Marc D BeerExecutive Chairman, DirectorBought115,950$1.53$177,404Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score6 of 84 of 85 of 8
Rule of 4026.7%26.1%13.2%
Altman Z''4.65−0.520.97
Accruals ratio−17.7%−30.3%−7.1%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassPassPass
Cash from operations is positivePassPassPass
Return on assets rosePassFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPassPassFail
Current ratio rosePassFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsFailFailPass
F-score6 of 84 of 85 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put biote side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
bioteFY25−2.5%18.5%15.7%—2.0x5
LifeMDFY2525.3%−4.0%3.3%———Compare
Strata Critical MedicalFY2534.3%−11.3%−29.7%−11.3%—4Compare
SBC Medical GroupFY25−15.5%38.9%13.4%38.4%−1.7x4Compare
AirSculpt TechnologiesFY25−15.8%−7.6%0.5%−6.6%39.0x3Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

5 years of figures

Fiscal yearFY21FY22FY23FY24FY25
Income statement
Revenue139165185197192
Revenue growth—18.3%12.4%6.4%−2.5%
Gross profit—————
Research and development—————
Operating income35−61293236
Net income11−13327
Diluted EPS (US$)—−0.120.130.090.74
Diluted shares (millions)—8263437
Cash flow
Cash from operations34−9274535
Capital expenditure10065
Free cash flow32−9273930
Dividends paid1113952
Share buybacks00063
Acquisitions000120
Stock-based compensation—82999
Balance sheet at fiscal year end
Cash and short-term investments079893924
Debt incl. finance leases37122116109103
Total assets54112155122108
Total liabilities50170192225158
Shareholders' equity4−44−29−106−58
Margins and ratios
Gross margin—————
Operating margin24.8%−36.8%15.5%16.0%18.5%
Net margin8.0%−0.6%1.8%1.6%14.1%
Free cash flow margin23.1%−5.8%14.3%19.7%15.7%
Rule of 40 (growth + FCF margin)—12.6%26.7%26.1%13.2%
Return on capital—−370.8%———
Return on equity—————
Return on assets—−1.2%2.5%2.3%23.5%
Net debt to EBITDA1.0x—0.8x2.0x2.0x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: biote's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with biote.